Strategies for media.ng the toxicity of prion proteins. Katrina A. Diaz Burke Group Literature Seminar 11/23/13

Similar documents
1997 Nobel Prize in Physiology or Medicine Dr. Stanley Prusiner

Prions Other molecules besides organelle DNA are inherited in non-mendelian patterns.

Novel Anti Prion Compounds Identified by Targeting a Functional Activity of PrP C

Prions and prion diseases. Bi156 lecture, 2/13/12

Targeting the Functional Activity of PrP C as a Novel Strategy for Drug Discovery in Prion Diseases

Mutations and Disease

Pr oject Summar y. Development of a diagnostic assay for chronic wasting disease. Principal Investigator: Richard Rubenstein

Prions show their metal

TSE S U.S. ENFORCEMENT STRATEGIES AND WHAT THEY MEAN TO YOU.

Prions A Challenge and Informative Paradigm for the Cleaning and Disinfection of Medical Devices

Inactivation of Prions: Studies in France & Germany

ASEAN TMHS SCIENTIFIC COMMITTEE PROJECT

RECENTLY, concerns have been raised about the potential

Progress in detecting prions and diagnosing prion diseases. Byron Caughey TSE/Prion Biochemistry Section, LPVD, Rocky Mountain Labs

New hospital Prion Disinfection Processes Compatible with Thermo- Sensitive Medical Equipment

Polypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab

LiveReceptor AMPAR <Endogenous AMPAR Labeling Reagent>

VHP Sterilization and Prion Inactivation

Pr oject Summar y. PrP genetics and expression in white-tailed deer. Principal Investigator: Judd Aiken. University of Wisconsin

RATIONAL TARGETING FOR PRION THERAPEUTICS

The Expression of Recombinant Sheep Prion Protein (RecShPrPC) and its Detection Using Western Blot and Immuno-PCR

Searching for Custom Dominant Negative PrPs by In Vitro Prion Replication Studies

Prion Diseases: toward further reduction of animal experimentation

Advances in hydrogen peroxide gas plasma sterilization

C 24/6 Official Journal of the European Union

Studies on Pathogenic Mechanisms of Prion Diseases and Evaluation of Prion Strains Properties

Method for Folding of Recombinant Prion Protein to Soluble β-sheet Secondary Structure

Probing Structural Differences of Recombinant Prion Isoforms Using Fluorescence Spectroscopy

Bovine Spongiform Encephalopathy (BSE) Mad Cow Disease

Research Biochemicals. ANTIBODIES TO PRION PROTEINS

NOVEL MARKERS FOR NEURODEGENERATION

BEH.462/3.962J Molecular Principles of Biomaterials Spring 2003

Chapter 1 Prion. 1.1 General overview of prion and prion diseases

MINIMISING THE RISK OF TRANSMITTING ANIMAL SPONGIFORM ENCEPHALOPATHY AGENTS VIA HUMAN AND VETERINARY MEDICINAL PRODUCTS.

Methods for Differentiating Prion Types in Food-Producing Animals

LUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures

The intracellular localization and traffic of Shadoo protein

leading the way in research & development

Development of a radioimmunoassay for screening of prion diseases

The Reusable Surgical Instrument Cycle

Novel immuno and stem cell based therapies. Sendi Montanič, Uroš Rajčevič and Vladka Čurin Šerbec

Performance of cell viability and cytotoxicity assays on the IN Cell Analyzer 3000

Hitting the target in phenotypic drug discovery: Advances in receptor deconvolution

Cytosolic PrP can participate in prion-mediated toxicity

Cytomics in Action: Cytokine Network Cytometry

Plant Virology. introduction

Proteins and folding

Cytosolic PrP can participate in prion-mediated toxicity

Cytosolic PrP can participate in prion-mediated toxicity

A c t i v a t e R N A i w i t h P r e c i s i o n. Specifically elicit RNAi without dsrna. mrna binding region

Introduc)on to Pharmacology and Pharmacogenomics. Roxana Daneshjou May 9, 2013

West-life services and tools for structural biology

ANNEX III ADDITIONAL GUIDANCE ON SPECIFIC TYPES OF GM WORK

What is an Aptamer? smallest unit of repeating structure

Endoscope Washer Disinfector Cleaning Process Challenge Devices Research & Validation

RNA interference (RNAi) and its applica3ons. Carlos Camilleri

Jiali Li, Sukhvir P Mahal, Cheryl A Demczyk and Charles Weissmann

Alzheimer s Disease. Joachim Herz. STARS January 11, 2010

Transcription and Translation

Bio Cremation Alkaline Hydrolysis

SureSilencing sirna Array Technology Overview

Cellular Phenotyping of Secretory and Nuclear Prion Proteins Associated with Inherited Prion Diseases*

Mouse-Adapted Ovine Scrapie Prion Strains Are Characterized by Different Conformers of PrPSc

Identifying Pharmacological Chaperones for the Cellular Prion Protein using a Label-free Biochemical Assay on the EnSight Multimode Plate Reader

Prion protein NMR structure and species barrier for prion diseases

Introduction to Protein Purification

Structure of IgG and IgM

Strategy for Selecting NAb Assay Format

Skills Required by Pharmacologists and Physiologists in Today s Pharmaceu:cal Industry

Interaction of recombinant and diseaseassociated prion proteins with organic and mineral soil colloids

Sure, some prions can cause diseases, but others are turning out to be beneficial.

Oral NT-KO-003 for the Treatment of Multiple Sclerosis

Introduction to Assay Development

Delivering on the Promise of RNA- Based Therapeu;cs

Viral Genomes. Genomes may consist of: 1. Double Stranded DNA 2. Double Stranded RNA 3. Single-stranded RNA 4. Single-stranded DNA

Congdon et al. Molecular Neurodegeneration (2016) 1:62 DOI /s z

Data Sheet HVEM/NF-κB Reporter Jurkat Recombinant Cell Line Catalog # 79310

Supplementary Figure 1. Expressions of stem cell markers decreased in TRCs on 2D plastic. TRCs were cultured on plastic for 1, 3, 5, or 7 days,

DISCUSSIONS. Alternatives to Animal Bioassays for Prions. Prion bioassays and the Three Rs. Prions and prion diseases

Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007

Chapter 18. Viral Genetics. AP Biology

Pretaporter, a Drosophila protein serving as a ligand for Draper in the phagocytosis of apoptotic cells

ProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation

How to Interrogate Epigenetic Events in Live Cells

Chemistry Exam #2 Answer Key -- November 4, 2008 There are 6 pages

APTAMER SELECTION AND CELL CULTURE MODEL DEVELOPMENT FOR DIAGNOSIS OF CHRONIC WASTING DISEASE OF CERVIDAE

Genome edi3ng with the CRISPR-Cas9 system

Biotechnology Unit: Viruses

Approaches to Nanoparticle Targeting. Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology

The Effects of Superparamagnetic Iron Oxide Nanoparticles on Biofilm. Thousand Oaks High School AP Research STEM

Fuse-It Membrane Fusion

Accelerated high fidelity prion amplification within and across prion species barriers

sirna Overview and Technical Tips

FRAUNHOFER IME SCREENINGPORT

Prion diseases: pathogenesis and public health concerns

Prion Removal Strategies: Challenges and Solutions

Alternate Approaches Addressing Variability in ADCC Assay. Prabhavathy Munagala, Ph.D. United States Pharmacopeia, India October 28, 2014

Develop A Highly Similar" Biosimilar Compound: Lessons Learnt

Protein Structure/Function Relationships

Site directed mutagenesis, Insertional and Deletion Mutagenesis. Mitesh Shrestha

Transcription:

Strategies for media.ng the toxicity of prion proteins Katrina A. Diaz Burke Group Literature Seminar 11/23/13

PrP c vs. PrP sc hmp://en.wikipedia.org/wiki/prnp PrP (prion protein or protease- resistant protein); CD230 Physiological role not well understood Exists in mul.ple isoforms, 208 AA long GPI anchor to membrane

Proposed func.ons of PrPc T cell ac.va.on and hemopoie.c stem cell differen.a.on Cellular trafficking via clathrin- dependent endocytosis, cell signaling Behavior, sleep, and long term memory Synap.c ac.vity, and neuronal excitability Linden et al. (2008). P hysiol Rev 88: 673 728 Suppression of apoptosis Westergard L, Christensen HM, Harris DA (2007). Biochim Biophys Acta. 1772: 629 644 hmp://en.wikipedia.org/, hmp://www.sciencedaily.com/

PrPc vs. PrPsc PrPsc (scrapie) isoform Toxic conforma.onal isoform B- sheet dominated Protease- resistant aggrega.on behavior hmp://intheochem.fc.ul.pt/research/mms.html

Proposed mechanisms of toxicity LOF GOF SOF Westergard L, Christensen HM, Harris DA (2007). Biochim Biophys Acta. 1772: 629 644

Template- directed refolding model Maintained conversion and nucleated polymeriza.on requires ini.al seed- - REVERSIBLE Aguzzi, A., Sigurdson, C., & Heikenwaelder, M. (2008). Annu. Rev. pathmechdis. Mech. Dis., 3, 11-40.

Transmissible spongiform encephalopathies hmp://www.cdc.gov/ncidod/dvrd/cjd/index.htm Creutzfeldt- Jakob Disease (CJD) Variant Creutzfeldt- Jakob Disease (vcjd) Gerstmann- Straussler- Scheinker Syndrome Fatal Familial Insomnia Kuru Bovine Spongiform Encephalopathy (BSE) Chronic Was.ng Disease (CWD) Scrapie Transmissible mink encephalopathy Feline spongiform encephalopathy Ungulate spongiform encephalopathy

Drug- based, cellular assay of the neurodegenera.ve phenotype G418 Massignan, T. et al. J Biol Chem. 2010;285:7752 65. Zeocin

ΔCR- dependent hypersensi.vity cis, WT rescue in trans TUNEL assay: fluorescence assay that detects DNA fragmenta.on indica.ng dying cells Biasini, E. et al (2012). PloS one, 7(3), e33472.

Cis toxicity of ΔCR and trans rescuing ac.vity of WT PrP in HEK293 cells Biasini, E. et al (2012). PloS one, 7(3), e33472.

Models for ΔCR PrP cis- toxicity and WT PrP trans- rescue Biasini, E. et al (2012). PloS one, 7(3), e33472.

POM monoclonal an.bodies Development of an.bodies to probe the role of domains in binding of PrP c to PrP sc and cause toxicity Monoclonal made from clones of immune cells, monovalent affinity Polymenidou, M. et al. PLoS ONE 3, e3872 (2008)

Binding of POM an.body ligands can be toxic to neural.ssue Sona., T. et al. (2013). Nature, 501(7465), 102-106.

Cerebellar organotypic cultured slices show toxic effects of POM1 binding Sona., T. et al. (2013). Nature, 501(7465), 102-106.

Immunostaining for neural.ssue marker NeuN shows POM1 toxicity Sona., T. et al. (2013). Nature, 501(7465), 102-106.

POM1 is dose- dependent and can be protected against with exogenous PrP Sona., T. et al. (2013). Nature, 501(7465), 102-106.

Protec.ng against POM1 toxicity using various an.bodies and compounds Sona., T. et al. (2013). Nature, 501(7465), 102-106.

In vivo toxicity of POM1 Sona., T. et al. (2013). Nature, 501(7465), 102-106.

POM1 induces brain lesions in vivo that can be protected against by exogenous PrP Sona., T. et al. (2013). Nature, 501(7465), 102-106.

Conclusions FT region is the effector domain of PrP c - mediated neuronal death An.bodies bind to GD but FT must be present for toxicity to occur GD ligand binding toxicity may mimic binding of PrP c to PrP sc Therapeu.c implica.ons Soluble PrP c may reduce toxicity by binding up free PrP sc, preven.ng interac.on with membrane PrP c An.- GD autoimmunity may cause neurodegenera.on

Soluble prion protein inhibits amyloidogenesis of Aβ1 42 Nieznanski, K. et al. (2012). Journal of Biological Chemistry, 287(40), 33104-33108.

Soluble prion protein inhibits toxicity of Aβ1 42 in cell culture Nieznanski, K. et al. (2012). Journal of Biological Chemistry, 287(40), 33104-33108.

Outlook Cause for muta.on and misfolding How to prevent misfolding to begin with? Soluble WT prion protein as a therapeu.c in the clinic Issues with foreign protein Protease degrada.on Gene therapy- - overexpression of PrP c could make it worse, quicker infec.on Small molecule mimics of PrP c?